对比增强同相位Dixon序列对乳腺MRI活检夹检测的影响
本研究回顾性纳入164例患者共281枚乳腺活检夹,比较对比增强同相位Dixon序列与三种常规临床序列对活检夹的检测能力。结果显示Dixon序列的汇总敏感度(85.1%)高于T1加权非压脂(78.2%)、STIR(26.6%)和对比增强T1加权压脂(61.7%),且读者信心和CNR更高,PPV无显著差异。
要点
- 对比增强同相位Dixon序列检测活检夹敏感度最高(85.1%),优于常规序列。
- 该序列对活检夹的读者信心评分(3.5)和CNR(4.05)均最高。
- STIR序列检测活检夹敏感度仅26.6%,不宜单独用于夹子定位。
关键影像表现/征象
- 对比增强同相位Dixon序列上活检夹的平均CNR为4.05±2.6,高于T1加权NFS的1.21±0.61、STIR的0.57±0.69和对比增强T1加权FS的0.54±0.61。
- 对比增强同相位Dixon序列对真阳性评估的汇总平均信心评分为3.5±0.8,高于T1加权NFS的3.0±0.9、STIR的1.7±0.9和对比增强T1加权FS的2.5±1.0。
诊断标准与关键数值
- 对比增强同相位Dixon序列检测活检夹的汇总敏感度为85.1%,PPV为95.1%。
- T1加权NFS序列的汇总敏感度为78.2%,PPV为96.2%。
- STIR序列的汇总敏感度为26.6%,PPV为92.7%。
- 对比增强T1加权FS序列的汇总敏感度为61.7%,PPV为95.9%。
- Dixon序列敏感度高于其他序列(均p<.05),PPV与其他序列无显著差异(均p>.05);信心评分和CNR均高于其他序列(均p<.001)。
临床应用与阅片要点
- 在乳腺MRI中可使用对比增强同相位Dixon序列辅助检测活检夹,以提高检出敏感度和定位信心。
- STIR序列对活检夹检出敏感度低,阅片时不应依赖STIR序列判断夹子位置。
局限性
- 本研究为回顾性单中心研究。
- 原文未报告其他明显局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Identification of breast biopsy clips using conventional MRI sequences may be challenging. A contrast-enhanced in-phase Dixon sequence may have greater conspicuity for areas of susceptibility compared with standard clinical sequences. OBJECTIVE. The purpose of this article is to compare detection of breast biopsy clips on MRI between the contrast-enhanced in-phase Dixon sequence and three routine clinical sequences. METHODS. This retrospective study included 164 patients (mean age, 50.3 years) with a total of 281 breast biopsy clips who underwent contrast-enhanced breast MRI between January 2, 2019, and April 16, 2020. Three radiologists, blinded to the clip location and sequence used, independently annotated biopsy clip locations on three clinical sequences (T1-weighted non-fat-suppressed [NFS], STIR, and first phase from dynamic contrast-enhanced T1-weighted fat-suppressed [FS]) and on a contrast-enhanced in-phase Dixon sequence and then recorded confidence scores (1-4 scale). A study coordinator used all available imaging and reports to localize clips on MRI, which served as the reference standard. A physicist measured clip CNR. Sequences were compared using the McNemar test and two-tailed Wilcoxon signed rank tests. RESULTS. Among the three readers, pooled sensitivity and PPV were 78.2% and 96.2% for T1-weighted NFS, 26.6% and 92.7% for STIR, 61.7% and 95.9% for contrast-enhanced T1-weighted FS, and 85.1% and 95.1% for contrast-enhanced in-phase Dixon sequence. Pooled sensitivity was higher for contrast-enhanced in-phase Dixon sequence than for the other sequences (all p < .05); pooled PPV was not significantly different between contrast-enhanced in-phase Dixon and the other sequences (all p > .05). Mean confidence scores (pooled across readers for true-positive assessments) and mean CNR were 3.0 ± 0.9 (SD) and 1.21 ± 0.61 for T1-weighted NFS, 1.7 ± 0.9 and 0.57 ± 0.69 for STIR, 2.5 ± 1.0 and 0.54 ± 0.61 for contrast-enhanced T1-weighted FS, and 3.5 ± 0.8 and 4.05 ± 2.6 for the contrast-enhanced in-phase Dixon sequence. Pooled mean confidence scores and CNR were higher for contrast-enhanced in-phase Dixon than for the other sequences (all p < .001). CONCLUSION. Compared with clinical sequences, the contrast-enhanced in-phase Dixon sequence had higher sensitivity for detecting breast biopsy clips on MRI and higher reader confidence and CNR, without change in PPV. CLINICAL IMPACT. The contrast-enhanced in-phase Dixon sequence may help address a current challenge in clinical breast MRI interpretation.
引用
- Taylor-Cho, Robertson, Knight, et al. Contrast-Enhanced In-Phase Dixon Sequence: Impact on Biopsy Clip Detection on Breast MRI. AJR Am J Roentgenol. 2022. PMID: 36102728. doi:10.2214/AJR.22.28024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。